Moleculin secures Australian patent for Annamycin
Moleculin Biotech announced the grant of an Australian patent for its preliposomal Annamycin formulation technology. This strengthens the company's global intellectual property portfolio and development strategy.
AI-generated summary for informational purposes only. Always verify against the original filing. Not investment advice. BriefTape is not a registered investment adviser.
Get real-time financial news in your trading bot or app
START FREE — 10,000 calls/day, no key needed